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Abstract 
 
The primary goal of genomic medicine is to make use of and examine thean individua l’s 
genomic information to support the clinical decision-making process. At present, several 
international organizations and research consortia exist, which aim to support the translation of 
genomic research into clinical practice so that genomic medicine can ultimately be used to 
benefit the global community. The Genomic Medicine Alliance 
[http://www.genomicmedicinealliance.org] is a global academic research network that seeks to 
establish and strengthen collaborative ties between different genomic medicine stakeholders. 
Its focus lies firmly with the translation of scientific research findings into clinical practice. To 
this end, it brings together experts from various disciplines including genome informatics, 
pharmacogenomics, public health genomics, as well as experts on ethical, legal and social issues  
in the sphere of genomics/health economics. These multidisciplinary activities are supervised 
by a 15-member International Scientific Advisory Committee. Its official journal, Public Health 
Genomics, offers members a highly respected publication forum for reviews, original research 
findings and policy in this field. In the short-to-medium term, the Genomic Medicine Alliance 
aims to promote research collaborations between developed and developing countries and to 
organize educational activities in the field of genomic medicine. In the longer term, it aspires 
to become a focal point for global collaboration in the field of genomic medicine while helping 
to pave the way for a smoother transition from genomics research to genomic medicine. 
 
Key words: Genomic Medicine, pharmacogenomics, Ethics in Genomics (genethics), whole 
genome sequencing, genome informatics, public health genomics, economic evaluation in 
genomic medicine, genome literacy, genetics education 
Introduction 
 
Genomic medicine aims to utilize the individual’s genomic information to support the 
clinical decision-making process [Manolio et al., 2015]. In recent years, significant advances 
have been made to in understanding the molecular basis of a wide range of human inherited 
diseases and cancers with the potential to improve disease prognosis and treatment [Kilpinen 
and Barrett, 2013]. At the same time, genomic technology has progressed rapidly, with a variety 
of new high-throughput genome-wide screening and massively parallel sequencing approaches 
becoming available [Gullapalli et al., 2012]. As a result, genomic information is becoming more 
readily available with the potential to play a role in diagnosis, disease risk-stratification, 
medication selection and dosing, carrier screening and other emerging uses. This constitutes 
the basis of Genomic Medicine, a relatively new discipline that aims to enhance opportunit ies 
for disease prevention, and the customization of patient care, including the personalization of 
conventional and new therapeutic interventions [Lazaridis et al., 2014].  
Genomic Medicine is closely linked to the concept of or Personalized Medicine, which 
refers to the aim to tailor diagnosis and treatment more closely to the individual characteristics 
of patients [European Science Foundation, 2012]. Although personalized medicine as a concept 
has gained particular currency within the last two decades, its central concept was proposed 
around 400 B.C.; Hippocrates of Kos (460–370 B.C.) stated that “… it is more important to 
know what kind of person suffers from a disease than to know the disease a person suffers”. 
The first application of “Genomic Medicine” can be said to have been codified in the Talmud 
(Yevamot 64b), where it is stated [Rabbi Judah the Prince’s ruling (2nd century B.C.)] that if a 
woman’s first two children had died from blood loss after circumcision, the third son should be 
exempted from circumcision. Rabbi Simeon ben Gamliel disagreed and ruled that the third son 
might be circumcised, but if this infant also died then the fourth child should not be circumcised. 
These ancient examples could be seen to encapsulate the essence of personalized medicine  
where people’s personal circumstances and characteristics mean that not everybody is treated 
the same. Today, genomics yields important information for personalization. For this reason, 
several international organizations and research consortia have been formed with the stated goal 
of supporting the translation of genomic research into clinical practice so that genomic medicine 
can ultimately be used to benefit the global community. 
The Genomic Medicine Alliance [GMA; www.genomicmedicinealliance.org; Cooper 
et al, 2014] is a newly established global academic research network, which aims to build and 
strengthen collaborative ties between academics, researchers, regulators and those members of 
the general public interested in genomic medicine, focusing in particular on developing 
countries and low-resource environments.  
 
Aims and goals of the Genomic Medicine Alliance 
 
The GMA aims to: (a) Encourage and catalyze multidisciplinary collaborative research 
between partner institutions and scientists, with an emphasis on developing countries; (b) Liaise 
between research organizations, clinical entities and regulatory agencies on topics related to 
genomic medicine; (c) Facilitate the introduction of pharmacogenomics and advanced ‘omics 
technologies into mainstream clinical practice; (d) Propose international guidelines and draw 
up recommendations for activities pertaining to genomic medicine, in close collaboration with 
other scientific academic entities, agencies and regulatory bodies; and (e) Develop 
independently and coordinate, in close collaboration with partner institutions, educational 
activities in the area sphere of genomic medicine. 
The GMA aims to foster collaboration in genomics research between developed and 
developing/low resourced countries, seeking to ensure that such collaboration is beneficial to 
all parties concerned. Developing countries will should benefit from training opportunit ies, 
knowledge exchange, and expanding transnational networks whereas developed countries 
could expect to benefit through comparative work on ethnically diverse populations that have 
not yet been well studiedcurrently characterized, and by having access to families with rare 
diseases or unique clinical features, especially where the developing countries are characterized 
by a higher incidence of consanguinity and/or well-defined founder populations (see also 
below). This includes patients coming from ethnic communities within developed countries that 
are characterized by a high rate of consanguineous marriages. Considering that approximately 
85% of the world’s population live in developing countries, this represents a major challenge 
to access and engage a hitherto neglected group of individuals with rare diseases [Cooper et al., 
2014]. Rare diseases are not only important in terms of improving our understanding of the 
pathology to benefit the affected patients and their families, but they have the potential to 
provide key insights that can lead to a better understanding of gene function in both health and 
disease [Collins, 2011].  
A key aim of GMA is paving the way from genomics research to Genomic Medicine, 
by encouraging and undertaking multicenter research projects in key sub-disciplines. To this 
end, GMA activities aim to contribute to the transition from genomics and pharmacogenomics 
research to Genomic Medicine, viz. Public Health Genomics, Ethics in Genomics (or 
‘genethics’), Genome Informatics, the genetics education of healthcare professionals, the 
genetics awareness of the general public and health economic evaluation in relation to genomic 
medicine. This has been previously represented pictorially as an ancient Greek temple, where 
genomics and pharmacogenomics research represents the bedrock of genomic medicine, and 
where the various subdisciplines are held above the supporting pillars that must be carefully 
erected for the superstructure of Genomic Medicine to hold (Fig. 15.1). At present, although 
the foundations of genomic medicine are becoming stronger and being ascribed ever-increasing 
hopes and expectations, the pillars themselves are still largely under construction.  
 
<Insert Figure 15.1 near here> 
 GMA research activities are supervised by an International Scientific Advisory 
Committee comprising 16 internationally renowned scientists in the field from all over the 
world (Table 15.1). Administrative assistance is provided by the Golden Helix Foundation 
(www.goldenhelix.org) staff. Registration with the GMA is free-of-charge in order to 
encourage the participation of researchers from developing/low income countries and emerging 
economies. Upon registration, members specify their research interests so that they can be 
directed to research projects and training opportunities that suit their specific needs.  
 
<Insert Table 15.1 near here> 
 
The GMA has recently established the concept of ‘GMA Ambassadors’ within the 
network, aiming to actively engage dynamic, mostly early-career but also senior scientists with 
a keen interest in Genomic Medicine, who are interested in expanding the GMA network in 
their own territory. In particular, the role of GMA Ambassadors is will be to (a) increase 
awareness of GMA activities and events among their peers and colleagues, (b) attract new 
members to the GMA through social media and other means, (c) contribute and/or comment on 
articles posted on the GMA portal, pertaining to their area of expertise and territories, and (d) 
represent the GMA, if required, at scientific events and conferences that the GMA Ambassadors 
attend. 
 GMA research activities span eight different Working Groups: Genome Informatics, 
Pharmacogenomics, Cancer Genomics, Public Health Genomics, Genethics and Economic 
Evaluation in Genomic Medicine. Each of the Working Groups’ activities are coordinated by 
the corresponding Working Group and Activity leaders in conjunction with Senior National 
Representatives from each of the >70 countries from which the >1200 current GMA members 
(January 2017) originate. Some of the key GMA research projects are outlined below. 
 Current research projects among GMA members 
 
Pharmacogenomics Working Group  
Pharmacogenomics aims to rationalize drug treatment by optimizing the balance 
between treatment efficacy and toxicity based on a comprehensive understanding of the impact 
of genomic variants on drug metabolism combined with other patient-based and environmental 
factors. The GMA Pharmacogenomics Working Group, in close collaboration with the Golden 
Helix Foundation, is currently taking part in the Euro-PGx project 
[http://www.goldenhelix.org/index.php/research/pharmacogenomics-in-europe], in which 26 
European populations are participating. More specifically, the Euro-PGx project aims to (a) 
determine the population-specific allele frequencies of pharmacogenomics variants to optimise 
medication choice and dose and minimize adverse reactions by genotyping 1,936 
pharmacogenomically-relevant genetic variants in 231 absorption, distribution, metabolism and 
excretion–toxicity (ADMET)-related pharmacogenes, which would assist in prioritizing 
medication selection in participating developing countries and, (b) develop off-the-shelf 
solutions for pharmacogenomic testing in participating developing countries. There are 
significant inter-population pharmacogenomic allele frequency differences, particularly in 
seven clinically actionable pharmacogenes in seven European populations that affect drug 
efficacy and/or toxicity of 51 medication treatment modalities. This includes differences 
observed in the prevalence of high-risk genotypes in these populations in the CYP2D6, 
CYP2C9, CYP2C19, CYP3A5, VKORC1, SLCO1B1 and TPMT pharmacogenes, resulting in 
notable differences in drug response, such as the genotype-based warfarin dosing within 
between these populations [Mizzi et al., 2016]. These findings can be used not only to develop 
guidelines for medication prioritization, but most importantly to facilitate the integration of 
pharmacogenomics and to support pre-emptive pharmacogenomic testing. Replication of these 
findings in larger population samples would permit the establishment of a rational framework 
for pharmacogenomic testing in developing countries that to supports the incorporation of 
country-specific population characteristics in a standardized fashion. 
At the same time, the GMA Pharmacogenomics Working Group has sought to provide  
proof-of-principle of the use of whole-genome sequencing for pharmacogenomic testing, by 
resequencing with high coverage almost 500 whole genomes, mostly from Caucasian 
populations. This project not only revealed a vast number of novel potentially functional 
variants in a total of 231 pharmacogenes, as indicated by in silico analysis, but has also 
demonstrated the value of whole-genome sequencing for pharmacogenomic testing by 
capturing over 18,000 variants in these pharmacogenes, in contrast to just over 250 variants that 
would have been identified in these genes using the most comprehensive pharmacogenomics 
assay currently available [Mizzi et al., 2014]. 
 
Genome Informatics Working Group 
Documentation of the incidence of genetic disorders in different populations , 
particularly in those developing countries with a high incidence of genetic diseases and/or 
consanguinity can be particularly helpful in the context of adopting national prevention and 
screening programs [Patrinos, 2006]. GMA members have actively participated in the 
development of new or the update of existing National/Ethnic Genetic databases for several 
populations in GMA member territories, such as Greece, Serbia, Kuwait, Egypt and Tunisia, 
using the newly upgraded ETHNOS software [Viennas et al., 2017].  
The result is that the ETHNOS software supports, in its present format, the development 
of National Genetic databases [Papadopoulos et al., 2014], based on the data warehouse 
principle and pre-existing guidelines [Patrinos et al., 2011]. These databases will be assigned 
to senior human geneticists in the corresponding populations in order to coordinate their 
curation and stimulate data enrichment and expansion. 
 Cancer Genomics Working Group 
Identification of genomic variants and structural alterations that guide therapy selection 
for patients with cancer has nowadays become routine in many clinical centres. The majority 
of genomic assays used for solid tumour profiling use employ next-generation resequencing to 
interrogate mostly somatic but also germline variants because they can be relatively more 
easilyer identified and interpreted.  
Owing to the rapid evolution of next generation sequencing, the past decade has seen 
the characterization of nucleic acidboth somatic and/or germline alterations in a wide range of 
cancers generating a large body of information pertaining to how cancer develops, evolves, and 
reacts to various treatment modalities [Macintyre et al., 2016]. Also, a considerable number of 
genomic variants have been previously been reported to be causative of, or associated with, 
tumor progression or an increased risk for various types of cancer [Hanahan and Weinberg, 
2011]. The GMA Cancer Genomics Working Group aims to define some of the key tools for 
genomic testing that primary care practitioners and specialists should know about when 
considering how to treat cancer patients.  
At the same time, members of the GMA Cancer Genomics Working Group have 
undertaken a study to identify cancer predisposition (germline) variants in apparently healthy 
individuals with no cancer history in the family using a next-generation sequencing strategy. 
Such an approach aimed to identify genomic, particularly novel, variants that might predispose 
to various types of cancer so that such information could help in the assessment of personalized 
cancer-susceptibility risk from genome sequence data [Karageorgos et al., 2015]. This includes 
both genomic variants in genes (like e.g. BRCA1/2 genes) that are have previously been 
associated with heritable risk conditions, and also risk alleles that are known to increase cancer 
predisposition risk, but not in a Mendelian sense. Indeed, a small fraction (3%) of a large 
number of variants (571 variants in total) previously associated with cancer predisposition has 
been shown to be potentially pathogenic in the members of two families. This approach could 
be adopted for other types of complex genetic disorder in order to identify variants of potential 
pathological significance. 
 
Public Health Genomics Working Group  
Public Health Genomics represents the responsible and effective translation of genome-
based knowledge and technologies into public policy and health services for the benefit of 
population health [Burke et al., 2006]. The GMA Public Health Genomics Working Group is 
undertaking national and transnational studies to improve our understanding of the level of 
public awareness of genetics, including their attitudes to genomic testing and the level of 
genetics education of healthcare professionals (i.e. physicians, pharmacists, etc). So far, such 
surveys have yielded some very interesting findings [Mai et al., 2014] highlighting the relative 
lack of genetics education of healthcare professionals and genetic awareness and literacy of the 
general public as perhaps some of the biggest obstacles to the widespread implementation of 
Genomic Medicine [Kampourakis et al., 2014]. A detailed stakeholder analysis which aimed to 
comprehend the attitudes and map the genomic medicine policy environment was undertaken, 
serving as a database for assessments of the policy’s content, the major players, their power and 
policy positions, their interests and networks and coalitions that interconnect them 
[Mitropoulou et al., 2014]. These findings should contribute to the selection and 
implementation of policy measures that will expedite the adoption of genomics into 
conventional medical interventions; such studies are currently being replicated in other 
countries, under the umbrella of the GMA. 
These studies have also shown the general utility of genomic testing for individua ls 
including the public’s remarkable level of interest in participating in genomic research [Reydon 
et al., 2012; Demmer and Waggoner, 2014]. Such surveys have already been replicated in other 
European countries [Pisanu et al., 2014; submitted] and are currently being conducted in 
Southeast Asia and the Middle East, partly supported by the Golden Helix Foundation, thereby 
confirming initial findings and highlighting the need to harmonize genomics education and to 
raise genomics awareness among the general public. To this end, GMA members co-organize 
educational events revolving around pharmacogenomics and genomic medicine in various 
European countries; these are endorsed by the GMA and partly funded by the Golden Helix 
Foundation and other entities [Squassina et al., 2012]. 
 
Genethics Working Group  
Several ethical issues confront those who are committed to the practice of Genomic 
Medicine, including the regulation of genetic testing, the governance of genetic research, and 
genomic data sharing in an ethical and publicly accountable way [Kampourakis et al., 2014]. 
The GMA Genethics Working group also explores the landscape of direct-to-consumer (DTC), 
beyond the clinic [Prainsack and Vayena, 2013] and over-the-counter (OTC) genetic tests in 
various European countries, including Greece, Slovenia, Italy and Serbia. From these 
undertakings, it is particularly important to harmonize policies that safeguard the general public 
and ensure that they become better informed with respect to the various attendant risks from 
this type of testing. Currently, regulation of these issues is lacking in many European countries, 
as well as at a central level in the form of a directive of the European Medicines Agency for 
both OTC and DTC genetic testing [Kricka et al., 2011]. The GMA has recently produced an 
opinion article to highlight the various types of OTC genetic tests currently available [Patrinos 
et al., 2013]. GMA members are also working in close cooperation with the National Genetic 
Societies and National Ethics Committees to establish guidelines to cover ethical, legal and 
social issues pertaining to genetic testing.  
Furthermore, in an effort to resolve the ambiguity regarding the utility of nutrigenomics 
testing given our current level of knowledge, the GMA Public Health Genomics Working 
Group has encouraged the meta-analysis of a number of studies related to 38 genes included in 
nutrigenomics tests provided by various private genetic testing laboratories, aiming to identify 
possible associations between the genes of interest and dietary intake and/or nutrient-related 
pathologies. No specific and statistically significant association was observed for any of the 38 
genes, while in those cases where a weak association was demonstrated, evidence was based 
on a limited number of studies [Pavlidis et al., 2015]. This study has demonstrated that although 
nutrigenomics research is a promising area for genomic investigation, solid scientific evidence 
is currently lacking, and as such commercially available nutrigenomics tests cannot be 
recommended. This is consistent with the 2014 position statement from the Academy of 
Nutrition and Dietetics, indicating that ‘‘It is the position of the Academy of Nutrition and 
Dietetics that nutritional genomics provides insight into how diet and genotype interactions 
affect phenotype’’ [Camp and Trujillo, 2014]. On the contrary, it has been suggested that 
assessment and synthesis of nutrigenomics data should be carried out on an ongoing basis at 
periodic intervals and/or when there is a specific demand for a synthesis of the available 
evidence, and importantly, in ways that are transparent where potential conflict of interests are 
fully disclosed by the parties involved [Pavlidis et al., 2016].  
 
Economic Evaluation in Genomic Medicine Working Group  
A key factor in expediting the adoption of Genomic Medicine in clinical practice would 
be the demonstration of its cost-effectiveness (as the “fourth hurdle” in healthcare, after safety, 
efficacy and quality). The real cost- effectiveness of involving genomics in medicine is as yet 
unknown apart from some rather limited studies in pharmacogenomics and hereditary cancer 
syndromes. Although it is vital to perform cost-effectiveness analyses for the implementation 
of genomic medicine in developing countries, there are only a handful of such studies reported 
in the literature [Snyder et al., 2014]. Realizing cost-effectiveness would be a crucial step 
towards convincing policy makers of the utility of genomics in healthcare as a means to reduce 
the overall treatment costs, as well as to reduce the overall burden and minimize consequences 
of disease at the national level [Payne and Shabaruddin, 2010]. Currently, the GMA Economic 
Evaluation in Genomic Medicine Working Group has been successfully engaged in assessing 
the cost-effectiveness of genome-guided treatment modalities in developing countries. In 
particular, GMA members have participated in a prospective study to assess the cost-
effectiveness of genome-guided warfarin treatment in Croatia, where it has been shown that 
genome-guided warfarin treatment may represent a cost-effective therapy option for the 
management of elderly patients with atrial fibrillation who developed ischemic stroke in 
Croatia, with an estimated incremental cost-effectiveness ratio of the pharmacogenomics-
guided versus the control groups of €31,225/QALY  [Mitropoulou et al., 2015]. Also, a 
retrospective economic analysis for of genome-guided clopidogrel treatment in Serbia indicated 
that pharmacogenomics-guided clopidogrel treatment may represent a cost-saving approach for 
the management of myocardial infarction patients undergoing primary percutaneous coronary 
intervention in Serbia, saving €13 per person on average [GEORGE: per day, per annum? per 
treatment], deducted from a break-even point analysis [Mitropoulou et al., 2016].  
Members of the GMA Economic Evaluation in Genomic Medicine Working Group 
have developed and evaluated standardized methodologies for the economic evaluation of 
genomic medicine [Fragoulakis et al., 2016; 2017], which, in addition to the already existing 
battery of economic evaluation models in genomic medicine [Annemans et al., 2013], will be 
of the utmost importance as innovative tools for performing cost-effectiveness analyses in such 
a rapidly evolving discipline. To this end, the GMA has also endorsed the production of a 
related textbook, co-authored by two GMA Scientific Advisory Committee members, published 
by Elsevier/Academic Press in early 2015 [Fragoulakis et al., 2015].   
Lastly, the issue of pricing and reimbursement was the topic for the GMA Economic 
Evaluation in Genomic Medicine Working Group, given the lack of harmonization between 
pricing and reimbursement policies between European countries, contrary to the situation 
pertaining in the United States [Logue, 2003].  
As a first step, the general strategy towards pricing and reimbursement for genomic 
medicine in Europe has been outlined, providing an overview of the rationale and basic 
principles guiding the governance of genomic testing services, clarifying their objectives, and 
allocating and defining responsibilities among stakeholders, focusing on different EU 
countries’ healthcare systems. Particular attention was paid to issues pertaining to pricing and 
reimbursement policies, the availability of essential genomic tests, differing between various 
countries owing to differences in disease prevalence and public health relevance, the 
prescribing and use of genomic testing services according to existing or new guidelines, 
budgetary and fiscal control, the balance between price and access to innovative testing, 
monitoring and evaluation for cost-effectiveness and safety, and the development of research 
capacity [Vozikis et al., 2016].  
Subsequently, it is hoped that a more technical analysis would lead to a robust policy in 
relation to pricing and reimbursement in genomic medicine, thereby contributing to an effective 
and sustainable health-care system that will prove beneficial to the economy at large. 
 
Establishment of the DRIFT Consortium 
Consistent with one of the stated goals of the GMA, which is the fruitful engagement 
between research groups from developing and developed countries to study families with rare 
diseases or unique clinical features (especially countries with a higher incidence of 
consanguinity and/or well-defined founder populations), the GMA participated in the 
establishment of the DRIFT (Discovery Research Investigating Founder Population Traits) 
Consortium.  
In early 2016, a call for research collaboration was made by the Regeneron Genetics 
Center (RGC) and the GMA, aimed specifically at developing countries. DRIFT  aims to 
understand the genetic architecture of founder populations throughout the world with direct 
impact on human health and disease. The DRIFT Consortium aims to catalogue population-
specific allelic architecture, to understanding the biological and functional consequences of 
specific genomic variants identified, and to share and establish best-practice approaches to 
relieve disease burden in these populations. DRIFT is planning two tiers of collaboration 
models:  
a. Tier 1 aims to canvas the allelic architecture of the population by exome sequencing and 
DNA microarrays from relatively unrelated individuals. Several hundred de-identified 
samples will be analyzed at the RGC that will provide high-depth exome sequence and 
genome-wide association data, derived from DNA microarrays, to be returned to the 
collaborator free of charge. There would be no need to exchange phenotype information 
and if the joint sequence data were used for any genotype-phenotype analyses, the results 
would be shared with RGC. Most importantly, the collaborator is free to publish results  
derived from this effort. 
b. Tier 2 aims to establish a collaborative effort focused on novel gene discovery for 
phenotypes of mutual interest. In this tier, an academic collaboration model is established, 
where the collaborator and the RGC jointly develop the research plan. In this tier, a much 
larger number of DNA samples (100s to 10,000s) is provided by the collaborator and again, 
like Tier 1, RGC provides all exome sequence data to the collaborator free of charge. De-
identified phenotype data will be shared, data analyses of the combined sequence and 
phenotype data set are performed collaboratively and each party is free to use the data set 
for its own internal research. Again, collaborators are encouraged to publish results and 
each party is free to use published results for any and all purposes.  
A short form material transfer agreement is used to govern the collaboration in both 
Tiers. For both models, data and results will be broadly shared with the research community 
and if exciting new results are generated from a Tier 1 or Tier 2 collaboration, there will be the 
potential for the design and funding of follow-up “genotype-first call-back” studies for 
additional collaborative research to delve more deeply into biological mechanisms and 
pathways. Such an approach is expected to attract institutions and research groups from 
developing countries in Europe, Latin America and the Middle East, which have founder 
populations bearing some very important features readily available for analysis.    
 
Conclusions and future perspectives 
 
The GMA is a new initiative in the field of Genomic Medicine, with the primary goal 
to develop a network focusing on the translation of genomic knowledge into clinical use, with 
a special focus on the participation of developing countries and of low-resource settings.  
The GMA has several unique features as a research network, in which it differs from 
existing consortia and initiatives in this field [Manolio et al., 2015]. First, membership is free 
of charge, which is particularly usefulimportant to attract members from low-resource 
environments. Second, it has a flat governance structure, consisting ofcomprising the Scientific 
Advisory and the Steering Committees. Third, this network has a stated goal and commitment 
to bring together genomics research institutions from developing countries with those from 
developed countries [Cooper et al., 2014].  
Ever since its establishment, the expansion of the GMA membership base has 
progressed at a very rapid pace, currently consisting of over 1,300 members from >70 countries 
worldwide, from academia as well as from corporate and regulatory sectors, including 
developing countries in the Middle East, Asia and Latin America.  
 In 2014, an important milestone for GMA was the agreement with Karger to establish 
the international peer-reviewed journal, Public Health Genomics 
(http://www.karger.com/Journal/Home/224224), as the Official GMA journal [Patrinos and 
Brand, 2014]. Public Health Genomics is the leading bimonthly international journal, published 
by Karger (Editor-In-Chief: Prof. Angela Brand) and focusing on the translation of genome-
based knowledge and technologies into public health, health policies and healthcare as a whole. 
This partnership not only provides GMA members with a highly respected forum to publish 
their original research findings but also with discounts on the journal’s annual subscription, 
Open Access fees and Karger books. 
 In addition, and in order to support the trans-national mobility of students and junior 
researchers, the GMA plans to launch short- and long-term research fellowships for early-stage 
researchers from developing countries to pursue research in Centers of Excellence in developed 
countries. The GMA envisages doing this in collaboration with the Golden Helix Foundation 
and other charities. Last but not least, the GMA will continue to endorse conferences and 
educational activities in the field of Genomic Medicine in Europe, the Middle East, Latin 
America and Southeast Asia. Indeed, since 2014, the GMA has established, in conjunction with 
the Golden Helix Foundation, the Golden Helix Summer Schools  
(http://summerschools.goldenhelix.org; see also next Chapter). This international initiative in 
the field of Genomic Medicine and Genome informatics aims to provide researchers around the 
world with the opportunity to expand their knowledge in these rapidly evolving disciplines.  
 In essence, the GMA aspires to become a focal point for harmonizing research activities 
in the field of genomic medicine between developed and developing countries while helping to 
pave the way for a smoother transition from genomics research to genomic medicine. 
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Figure 15.1 
 
Graphical depiction of the GMA research activities  that aim to translate Genomics Research 
and Pharmacogenomics into Genomic Medicine (see text for details). Research disciplines are 
listed in alphabetical order and (this order does not imply any prioritization of research activity). 
 
 
 
 
  
Table 15.1. 
Members of the GMA International Scientific Advisory Committee (in alphabetical order per 
by continent).  
 
Continent No Member Country  
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2 Ming Ta Michael Lee Japan 
Americas 3 Paolo Fortina USA 
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7 David N. Cooper United 
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8 Vita Dolzan Slovenia 
9 Milan Macek Jr Czech Republic 
10 George P. Patrinos Greece 
11 Barbara Prainsack United Kingdom 
12 Ron H. van Schaik The Netherlands 
13 Alessio Squassina Italy 
14 Domenica Taruscio Italy 
15 Effy Vayena Switzerland 
16 Athanassios Vozikis Greece 
17 Bauke Ylstra The Netherlands 
 
 
